Influence of Lipophilicity on the Antibacterial Activity of Polymyxin Derivatives and on Their Ability to Act as Potentiators of Rifampicin.
Novel polymyxin derivatives are often classified either as having direct activity against Gram-negative pathogens or as compounds inactive in their own right, which through permeabilization of the outer membrane act as potentiators of other antibiotics. Here, we report the systematic investigation of the influence of lipophilicity on microbiological activity (including against strains with reduced susceptibility to polymyxins), potentiation of rifampicin, and in vitro toxicity within a series of next-generation polymyxin nonapeptides. We demonstrate that the lipophilicity at the N-terminus and amino acids 6 and 7 in the cyclic peptide core is interchangeable and that the activity, ability to potentiate, and cytotoxicity all appear to be primarily driven by overall lipophilicity. Our work also suggests that the characterization of a polymyxin molecule as either a direct acting compound or a potentiator is more of a continuum that is strongly influenced by lipophilicity rather than as a result of fundamentally different modes-of-action.
['Brown|Pamela|P|0000-0002-1829-3695', 'Abdulle|Omar|O|', 'Boakes|Steven|S|', 'Divall|Naomi|N|', 'Duperchy|Esther|E|', 'Ganeshwaran|Sonia|S|', 'Lester|Roy|R|', 'Moss|Stephen|S|', 'Rivers|Dean|D|', 'Simonovic|Mona|M|', 'Singh|Jaspal|J|', 'Stanway|Steven|S|', 'Wilson|Antoinette|A|', 'Dawson|Michael J|MJ|']
D000900:Anti-Bacterial Agents D011113:Polymyxins D012293:Rifampin
lipophilicity polymyxin potentiator Gram-negative antimicrobial resistance multidrug-resistant bacteria